ArticleMolecular neurobiology2026
The Canonical Wnt Surrogate Agonist scFv-Dkk1c Ameliorates Spinal Cord Injury in Rats.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Despite the therapeutic potential of canonical Wnt/β-catenin signaling activation in spinal cord injury (SCI), the development of Wnt-based therapeutic approaches is severely hampered by difficulties in Wnt ligand production, their high receptor cross-reactivity and the unspecificity of glycogen synthase kinase-3β inhibitors. Consequently, the generation of chimeric canonical Wnt surrogates that can overcome the previously detailed limitations has been of paramount importance for the development of Wnt-based therapeutic approaches, although their potential beneficial role in SCI has not been assessed to date. For this purpose, we have evaluated the effects exerted by the overexpression of the canonical Wnt surrogate scFv-Dkk1c in a clinically relevant model of SCI in critical injury-related aspects such as motor functional recovery, myelin preservation/loss, neuronal cell density, microglia/macrophage and astroglial reactivity, expression of markers related to astroglial and microglia/macrophage polarization, vascularization and descending serotonergic innervation. Briefly, we found that scFv-Dkk1c overexpression during the progression of SCI significantly improved motor functional recovery concomitant with changes in the SCI-associated microglia/macrophage reactivity, expression of markers related to microglia/macrophage polarization, astroglial reactivity and tissue vascularization, without affecting myelin preservation/loss, neuronal cell density, expression of markers related to astroglial polarization, NG2 + cell presence and descending serotonergic innervation. In conclusion, the present study provides experimental evidence for the potential role of the canonical Wnt surrogate scFv-Dkk1c in the context of SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.